Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D004338:Drug Combinations / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D001391:Azo Compounds; D004338:Drug Combinations; D005472:Fluorouracil